Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ascendis Pharma A/S

174.96
-1.5300-0.87%
Post-market: 174.960.00000.00%17:23 EDT
Volume:387.28K
Turnover:67.87M
Market Cap:10.59B
PE:-27.80
High:177.18
Open:176.42
Low:173.78
Close:176.49
Loading ...

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
02 Jun

Ascendis' New Drug Application for Investigational Drug to Treat Genetic Disorder Accepted by FDA for Priority Review

MT Newswires Live
·
02 Jun

Ascendis Pharma A/S Secures Australian Regulatory Approval for SKYTROFA®, a New Once-Weekly Therapy for Paediatric Growth Hormone Deficiency

Reuters
·
30 May

European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading

MT Newswires Live
·
29 May

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

MT Newswires Live
·
14 May

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires Live
·
13 May

Ascendis says Phase 2 data shows ‘sustained response’ to TransCon PTH therapy

TIPRANKS
·
13 May

Ascendis Pharma Price Target Maintained With a $200.00/Share by Cantor Fitzgerald

Dow Jones
·
12 May

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Down 1% for Week

MT Newswires Live
·
09 May

Ascendis Likely to Benefit From Promising Yorvipath Launch, Morgan Stanley Says

MT Newswires Live
·
05 May

Ascendis Pharma announces it will share latest data at ESPE & ESE 2025

TIPRANKS
·
05 May

Morgan Stanley Upgrades Ascendis Pharma to Overweight From Equalweight, Boosts Price Target to $250 From $180

MT Newswires Live
·
05 May

Ascendis Pharma Raised to Overweight From Equal-Weight by Morgan Stanley

Dow Jones
·
05 May

Stock Track | Ascendis Pharma Soars 7.44% Pre-Market on Strong Q1 Results and Analyst Upgrades

Stock Track
·
02 May

Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
02 May

Ascendis Pharma a/S : Leerink Partners Raises Target Price to $200 From $190

THOMSON REUTERS
·
02 May

RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk

MT Newswires Live
·
02 May

Ascendis Pharma AS (ASND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

GuruFocus.com
·
02 May

Ascendis Pharma A/S reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
02 May

Ascendis Pharma Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
02 May